

This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Inflammation				
HCV	Not applicable	<p>A study in cells identified small molecule inhibitors of viral entry that may help treat HCV. In an HCV cellular assay, a triazine-based inhibitor reduced levels of infection compared with a control compound. The entry inhibitor plus an HCV non-structural protein 5A (NS5A) RNA polymerase inhibitor, an NS3 protease inhibitor or interferon-α (IFNα; IFN-α) reduced infection compared with the entry inhibitor alone. Next steps could include testing the inhibitors in chimeric mice with human livers.</p> <p>ITX5061, a small molecule entry inhibitor from iTherX Pharmaceuticals Inc., is in Phase II testing for HCV.</p> <p>SciBX 3(37); doi:10.1038/scibx.2010.1124 Published online Sept. 23, 2010</p>	Patent and licensing status undisclosed	<p>Baldick, C.J. <i>et al. PLoS Pathog.</i>; published online Sept. 2, 2010; doi:10.1371/journal.ppat.1001086</p> <p>Contact: Carl J. Baldick, Bristol-Myers Squibb Co. Research and Development, Wallingford, Conn. e-mail: joe.baldick@bms.com</p>